FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416083307> ?p ?o ?g. }

• W2416083307 endingPage "1205" @default.
• W2416083307 startingPage "1198" @default.
• W2416083307 abstract "A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent. The rationale of the study was based on the negative prognostic value of MDR phenotype in ALs and the ability of quinine to reverse this phenotype both in vitro and ex vivo. Three hundred fifteen patients (median age, 49 years; range, 16 to 65) with relapsed (n = 108) or refractory (n = 32) acute myeloblastic leukemia (AML), relapsed (n = 27) or refractory (n = 9) acute lymphoblastic leukemia (ALL), secondary AL (n = 22) or blastic transformation of myelodysplastic syndrome ([MDS] n = 74) or myeloproliferative syndrome ([MPS] n = 43) were randomly assigned to receive mitoxantrone ([MXN] 12 mg/m2/d, days 2 to 5) and cytarabine ([Ara-C] 1 g/m2/12 h, days 1 to 5) alone or in combination with quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before MXN infusion). Side effects of quinine were observed in 56 of 161 quinine-treated patients and disappeared in all but four cases after one or two 20% dose decreases. Sera from quinine-treated patients showed increased MXN uptake in an MDR-positive cell line compared with matched sera obtained before quinine infusion. Quinine induced a significant increase in the incidence of nausea, vomiting, mucositis, and cardiac toxicity. A complete response (CR) was observed in 85 of 161 patients (52.8%) from the quinine-treated group versus 70 of 154 patients (45.5%) in the control group (P = .19). The most important differences between quinine and control group CR rates were observed in patients with refractory AMLs and blastic transformation of MDS and MPS. The CR rate was higher in P-glycoprotein-positive cases, although the difference was not significant. Failure of the regimen due to blastic persistence or blast number increase was higher in the control group (61 of 154 patients) than in the quinine group (45 of 161, P = .04). Early death was observed in eight cases (four in each arm) and death in aplasia in 27 cases (20 in quinine group v seven in control group, P = .01). The significant increase of toxicity in the quinine arm could have masked the clinical benefit of MDR reversion in poor- risk ALs." @default.
• W2416083307 created "2016-06-24" @default.
• W2416083307 creator A5002061358 @default.
• W2416083307 creator A5005908128 @default.
• W2416083307 creator A5014723513 @default.
• W2416083307 creator A5023810956 @default.
• W2416083307 creator A5024260899 @default.
• W2416083307 creator A5031879677 @default.
• W2416083307 creator A5032008939 @default.
• W2416083307 creator A5037324033 @default.
• W2416083307 creator A5041108107 @default.
• W2416083307 creator A5046436694 @default.
• W2416083307 creator A5052935862 @default.
• W2416083307 creator A5069931565 @default.
• W2416083307 creator A5073836275 @default.
• W2416083307 creator A5075950291 @default.
• W2416083307 creator A5081817578 @default.
• W2416083307 creator A5084447104 @default.
• W2416083307 creator A5090367243 @default.
• W2416083307 date "1996-08-15" @default.
• W2416083307 modified "2023-10-15" @default.
• W2416083307 title "Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study" @default.
• W2416083307 cites W1211884343 @default.
• W2416083307 cites W1425315426 @default.
• W2416083307 cites W1545285984 @default.
• W2416083307 cites W1591796471 @default.
• W2416083307 cites W1723032639 @default.
• W2416083307 cites W174212352 @default.
• W2416083307 cites W1892479582 @default.
• W2416083307 cites W1915172695 @default.
• W2416083307 cites W1953437908 @default.
• W2416083307 cites W1966551433 @default.
• W2416083307 cites W1967960858 @default.
• W2416083307 cites W2000375621 @default.
• W2416083307 cites W2001030646 @default.
• W2416083307 cites W2009455363 @default.
• W2416083307 cites W2013276093 @default.
• W2416083307 cites W2017239698 @default.
• W2416083307 cites W2027981399 @default.
• W2416083307 cites W2032563753 @default.
• W2416083307 cites W2034529880 @default.
• W2416083307 cites W2035660841 @default.
• W2416083307 cites W2039257094 @default.
• W2416083307 cites W2043201907 @default.
• W2416083307 cites W2051099794 @default.
• W2416083307 cites W2076426515 @default.
• W2416083307 cites W2077753080 @default.
• W2416083307 cites W2078877172 @default.
• W2416083307 cites W2080798272 @default.
• W2416083307 cites W2082437291 @default.
• W2416083307 cites W2096830830 @default.
• W2416083307 cites W2102071915 @default.
• W2416083307 cites W2107965797 @default.
• W2416083307 cites W2118234018 @default.
• W2416083307 cites W2121476898 @default.
• W2416083307 cites W2138993111 @default.
• W2416083307 cites W2198835790 @default.
• W2416083307 cites W220750778 @default.
• W2416083307 cites W2228456847 @default.
• W2416083307 cites W2230711222 @default.
• W2416083307 cites W2395339981 @default.
• W2416083307 cites W2402721690 @default.
• W2416083307 cites W2410121974 @default.
• W2416083307 cites W2413652470 @default.
• W2416083307 cites W2424259720 @default.
• W2416083307 cites W2469926171 @default.
• W2416083307 cites W3146129082 @default.
• W2416083307 cites W329750643 @default.
• W2416083307 cites W58756698 @default.
• W2416083307 doi "https://doi.org/10.1182/blood.v88.4.1198.bloodjournal8841198" @default.
• W2416083307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8695837" @default.
• W2416083307 hasPublicationYear "1996" @default.
• W2416083307 type Work @default.
• W2416083307 sameAs 2416083307 @default.
• W2416083307 citedByCount "111" @default.
• W2416083307 countsByYear W24160833072012 @default.
• W2416083307 countsByYear W24160833072013 @default.
• W2416083307 countsByYear W24160833072014 @default.
• W2416083307 countsByYear W24160833072016 @default.
• W2416083307 countsByYear W24160833072019 @default.
• W2416083307 countsByYear W24160833072021 @default.
• W2416083307 countsByYear W24160833072022 @default.
• W2416083307 countsByYear W24160833072023 @default.
• W2416083307 crossrefType "journal-article" @default.
• W2416083307 hasAuthorship W2416083307A5002061358 @default.
• W2416083307 hasAuthorship W2416083307A5005908128 @default.
• W2416083307 hasAuthorship W2416083307A5014723513 @default.
• W2416083307 hasAuthorship W2416083307A5023810956 @default.
• W2416083307 hasAuthorship W2416083307A5024260899 @default.
• W2416083307 hasAuthorship W2416083307A5031879677 @default.
• W2416083307 hasAuthorship W2416083307A5032008939 @default.
• W2416083307 hasAuthorship W2416083307A5037324033 @default.
• W2416083307 hasAuthorship W2416083307A5041108107 @default.
• W2416083307 hasAuthorship W2416083307A5046436694 @default.
• W2416083307 hasAuthorship W2416083307A5052935862 @default.
• W2416083307 hasAuthorship W2416083307A5069931565 @default.
• W2416083307 hasAuthorship W2416083307A5073836275 @default.
• W2416083307 hasAuthorship W2416083307A5075950291 @default.

• next